New insights into the cardio-renal benefits of SGLT2 inhibitors and the coordinated role of miR-30 family.
SGLT2 抑制劑的心腎益處新見解及 miR-30 家族的協調作用。
Genes Dis 2024-09-03
[The mechanisms mediating the favorable effects of sodium-glucose cotransporter 2 inhibitors on cardiorenal function].
藉由鈉葡萄糖共同轉運蛋白2抑制劑對心腎功能產生有利效應的機制。
G Ital Cardiol (Rome) 2022-10-28
Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Sodium-Glucose Co-transporter-2 Inhibitors.
鈉葡萄糖共同轉運蛋白-2抑制劑對心血管和腎臟益處的臨床證據和機制建議。
touchREV Endocrinol 2023-02-01
[Renal effects of sodium-glucose cotransporter 2 inhibitors in patients with cardiovascular disease with and without chronic kidney disease].
心血管疾病患者中帶有和不帶有慢性腎臟疾病的鈉葡萄糖共同轉運蛋白2抑製劑的腎臟效應。
G Ital Cardiol (Rome) 2023-03-08
Reno- and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: from bedside to bench.
SGLT2抑制劑在糖尿病控制之外的腎臟和心臟保護分子機制:從臨床到實驗室。
Am J Physiol Cell Physiol 2023-10-12
Cardiovascular outcomes and molecular targets for the cardiac effects of Sodium-Glucose Cotransporter 2 Inhibitors: A systematic review.
SGLT2抑制劑對心臟效應的心血管結果和分子靶點:系統性回顧。
Biomed Pharmacother 2024-04-28
Mendelian randomization study of sodium-glucose cotransporter 2 inhibitors in cardiac and renal diseases.
鈉-葡萄糖共轉運蛋白 2 抑制劑在心臟病和腎臟病中的孟德爾隨機化研究。
J Int Med Res 2024-08-31